Natera, Inc. (NASDAQ:NTRA) Stock Holdings Reduced by Truist Financial Corp

Truist Financial Corp lowered its stake in Natera, Inc. (NASDAQ:NTRA) by 13.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,666 shares of the medical research company’s stock after selling 6,517 shares during the quarter. Truist Financial Corp’s holdings in Natera were worth $6,596,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Blue Trust Inc. lifted its position in shares of Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc lifted its position in shares of Natera by 345.8% during the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the last quarter. Principal Securities Inc. lifted its position in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Covestor Ltd lifted its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. Finally, True Wealth Design LLC acquired a new position in shares of Natera during the 3rd quarter worth about $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

NTRA stock opened at $162.31 on Friday. The firm has a market cap of $21.43 billion, a price-to-earnings ratio of -92.22 and a beta of 1.66. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $69.74 and a 12-month high of $183.00. The company’s fifty day simple moving average is $167.98 and its 200 day simple moving average is $145.54.

Analyst Ratings Changes

Several equities analysts recently weighed in on NTRA shares. Canaccord Genuity Group boosted their price objective on Natera from $165.00 to $180.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. TD Cowen boosted their price objective on Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Piper Sandler upped their price target on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Robert W. Baird upped their price target on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Barclays started coverage on Natera in a report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target for the company. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $170.94.

Insider Buying and Selling

In related news, insider John Fesko sold 663 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now owns 156,044 shares in the company, valued at $27,739,941.88. This represents a 0.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Roelof Botha sold 87,473 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the completion of the sale, the director now directly owns 1,224,787 shares of the company’s stock, valued at $207,135,977.44. The trade was a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 295,772 shares of company stock worth $49,741,699 in the last quarter. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.